Task 3.6
Nanobody labelling optimisation for PET and OI...
Description
General Design
- Type
- Cohort study
- Start/End data collection
- not available
Organisations
Lead organisations
- EBERHARD KARLS UNIVERSITAET TUEBINGENGermanyhttps://uni-tuebingen.de/en/
- PFIZER LIMITEDUnited Kingdom of Great Britain and Northern Ireland (the)https://www.pfizer.com/
- STICHTING VUMC (P1)Netherlands (the)https://www.vumc.nl/
- TAKEDA DEVELOPMENT CENTRE EUROPE LTDUnited Kingdom of Great Britain and Northern Ireland (the)
- University Medical Center Groningen (UMCG)Netherlands (the)http://www.umcg.nl
- VRIJE UNIVERSITEIT BRUSSELBelgiumhttps://www.vub.be/en/home
- WESTFAELISCHE WILHELMSUNIVERSITAET MUENSTERGermanyhttps://www.uni-muenster.de/en/
Additional organisations
- Antaros Medical (Sweden)Swedenhttps://antarosmedical.com/
- BAYER AKTIENGESELLSCHAFTGermanyhttps://www.bayer.com/en/
- F. HOFFMANN-LA ROCHE AGSwitzerlandhttps://www.roche.com/
- FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCASpain
- FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRONSpainhttps://www.vhio.net/
Data originator, Data holder, Data provider
- IMAGINAB, INCUnited States of America (the)https://imaginab.com/
- JANSSEN PHARMACEUTICA NVBelgiumhttps://www.janssen.com/belgium/
- STICHTING LYGATURENetherlands (the)https://www.lygature.org/
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGEUnited Kingdom of Great Britain and Northern Ireland (the)https://www.cam.ac.uk/
Networks
Part of networks...